Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Apthera, a biotechnology company focused on cancer immunotherapy, has announced an alliance with TGen Drug Development Services, under a master services agreement. TGen Drug Development Services is a wholly owned subsidiary of the Translational Genomics Research Institute.
Subscribe to our email newsletter
TGen Drug Development Services (TD2) will provide key drug development and regulatory services related to the clinical development of NeuVax, Apthera’s lead immunotherapy drug indicated for the adjuvant treatment of early-stage, lymph-node-positive breast cancer that contains the HER2 oncogene.
Apthera is currently preparing NeuVax for pivotal international Phase III clinical trials.
Alton Morgan, president and CEO of Apthera, said: “We feel that the extra capacity TD2 provides will help accelerate the development of our lead product, NeuVax, filling in vital, near-term responsibilities for our rapidly growing company.”